Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells

References

• Abdallah BM, Haack-Sorensen M, Burns JS, Elsnab B, Jakob F, Hokland P, Kassem M. Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite extensive proliferation. Biochem Biophys Res Comm 2005; 326: 527–38
   PubMed Web of Science ®Google Scholar
• Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009; 94: 1843–52
   PubMed Web of Science ®Google Scholar
• Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349–52
   PubMed Web of Science ®Google Scholar
• Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994; 134: 2156–64
   PubMed Web of Science ®Google Scholar
• Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076–84
   PubMed Web of Science ®Google Scholar
• Catena R, Santos E, Orive G, Hernández RM, Pedraz JL, Calvo A. Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple reporter system. J Control Release 2010; 146: 93–8
   PubMed Web of Science ®Google Scholar
• Chaikof EL. Engineering and material considerations in islet cell transplantation. Annu Rev Biomed Eng 1999; 1: 103–27
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126–31
   PubMed Web of Science ®Google Scholar
• Déglon N, Heyd B, Tan SA, Joseph JM, Zurn AD, Aebischer P. Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Hum Gene Ther 1996; 7: 2135–46
   PubMedGoogle Scholar
• Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet 2006; 368: 1696–705
   PubMed Web of Science ®Google Scholar
• During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173–9
   PubMed Web of Science ®Google Scholar
• Fletcher C, Sawchuk R, Chinnock B, de Miranda P, Balfour HH. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986; 40: 281–6
   PubMed Web of Science ®Google Scholar
• Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7: 2294–300
   PubMed Web of Science ®Google Scholar
• Golla R, Seethalam RA. Homogeneous enzyme fragment complementation cyclic AMP screen for GPCR agonists. J Biomol Screen 2002; 7: 515–25
   PubMedGoogle Scholar
• Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK. New therapeutic strategies and drug candidates for neurodegenerative diseases: P53 and TNF alpha Inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 2004; 1035: 290–315
   PubMed Web of Science ®Google Scholar
• Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: Potential therapeutic benefits beyond glycaemic control?. Br J Pharmacol 2009; 157: 1340–51
   PubMed Web of Science ®Google Scholar
• Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 2010; 159: 495–501
   PubMed Web of Science ®Google Scholar
• Heile AM, Wallrapp C, Klinge PM, Samii A, Kassem M, Silverberg G, Brinker T. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci Lett 2009; 463: 176–81
   PubMed Web of Science ®Google Scholar
• Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU, McIntosh CH. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 2002; 51: 652–61
   PubMed Web of Science ®Google Scholar
• Hinke SA, Manhart S, Kühn-Wache K, Nian C, Demuth HU, Pederson RA, McIntosh CH. [Ser2]- and [SerP2] incretin analogues: Comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo. J Biol Chem 2004; 279: 3998–4006
   PubMedGoogle Scholar
• Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011; 27: 547–58
   PubMed Web of Science ®Google Scholar
• Houtgraaf JH, Dejong R, Monkhorst K, Tempel D, Dendekker WK, Kazemi K, Hoefer I, Pasterkamp G, Lewis AL, Stratford PW, et al. Feasibility of intracoronary GLP-1 eluting CellBead infusion in acute myocardial infarction. Cell Transplant 2012, epub ahead of print
   PubMedGoogle Scholar
• Klinge PM, Harmening K, Miller MC, Heile A, Wallrapp C, Geigle P, Brinker T. Encapsulated native and Glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2011; 497: 6–10
   PubMed Web of Science ®Google Scholar
• Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, Bauer G, Nolta JA. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev 2010; 62: 1167–74
   PubMed Web of Science ®Google Scholar
• Murua A, Portero A, Orive G, Hernandez RM, Castro M, Pedraz JL. Cell microencapsulation technology: Towards clinical application. J Control Release 2008; 132: 76–83
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Mankad S, Sokos GG. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962–5
   PubMed Web of Science ®Google Scholar
• Orive G, Tam SK, Pedraz JL, Hallé JP. Biocompatibility of alginate-poly-L-lysine microcapsules for cell therapy. Biomaterials 2006; 27: 3691–700
   PubMed Web of Science ®Google Scholar
• Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002; 302: 881–8
   PubMed Web of Science ®Google Scholar
• Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010; 28: 585–96
   PubMed Web of Science ®Google Scholar
• Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG, Kassem M. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002; 20: 592–6
   PubMed Web of Science ®Google Scholar
• Smidsrød O, Skjåk-Braek G. Alginate as immobilization matrix for cells. Trends Biotechnol 1990; 8: 71–8
   PubMed Web of Science ®Google Scholar
• Sommadossi JP, Bevan R, Ling T, Lee F, Mastre B, Chaplin MD, Nerenberg C, Koretz S, Buhles WC, Jr. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis Suppl 1988; 3: 507–14
   Google Scholar
• Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review: Hitting the right spot with mesenchymal stromal cells. Stem Cells 2010; 28: 1446–55
   PubMed Web of Science ®Google Scholar
• Trouche E, Girod Fullana S, Mias C, Ceccaldi C, Tortosa F, Seguelas MH, Calise D, Parini A, Cussac D, Sallerin B. Evaluation of alginate microspheres for mesenchymal stem cell engraftment on solid organ. Cell Transplant 2010; 19: 1623–33
   PubMedGoogle Scholar
• Vos P, Bucko M, Gemeiner P, Navrátil M, Svitel J, Faas M, Strand BL, Skjak-Braek G, Morch YA, Vikartovská A, et al. Multiscale requirements for bioencapsulation in medicine and biotechnology. Biomaterials 2009; 30: 2559–70
   PubMedGoogle Scholar
• Wilson JT, Chaikof EL. Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv Drug Deliv Rev 2008; 60: 124–45
   PubMed Web of Science ®Google Scholar
• Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler MB. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 2001; 40: 2860–9
   PubMedGoogle Scholar
• Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, Yarmush ML. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010; 19: 667–79
   PubMed Web of Science ®Google Scholar
• Zhang R, Ma K, Xu L, Wallrapp C, Jonas JB. Intraocular cell-based production of glucagon-like peptide-1 in the anterior chamber. Acta Ophthalmol 2010; 88: 348–9
   Google Scholar
• Zimmermann U, Thürmer F, Jork A, Weber M, Mimietz S, Hillgärtner M, Brunnenmeier F, Zimmermann H, Westphal I, Fuhr G, et al. Novel class of amitogenic alginate microcapsules for long-term immunoisolated transplantation. Ann N Y Acad Sci 2001; 944: 199–215
   PubMed Web of Science ®Google Scholar